EC HCPCS Level II modifier: Erythropoietic stimulating agent (esa) administered to treat anemia not due to anti-cancer radiotherapy or anti-cancer chemotherapy
EC is a HCPCS Level II modifier: “Erythropoietic stimulating agent (esa) administered to treat anemia not due to anti-cancer radiotherapy or anti-cancer chemotherapy.” It adds this detail to the code it is reported with.
Official description
ECErythropoietic stimulating agent (esa) administered to treat anemia not due to anti-cancer radiotherapy or anti-cancer chemotherapy
Short description: Esa, anemia, non-chemo/radio
HCPCS · United States
Notes for EC
As CMS prints them, with any note EC takes from the headings above it.
Note
- CMS processing note 0147: CLAIMS PROCESSING MANUAL PUB 100-04, CHAPTER 17, SECTION 80.9.
Medicare details
The indicators CMS publishes with EC in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Added
- Jan 1, 2008
Where EC sits
- 1GroupHCPCS modifiers
- 2Modifier ECErythropoietic stimulating agent (esa) administered to treat anemia not due to anti-cancer radiotherapy or anti-cancer chemotherapy
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code EC mean?
EC is the HCPCS code for “Erythropoietic stimulating agent (esa) administered to treat anemia not due to anti-cancer radiotherapy or anti-cancer chemotherapy” in CMS’s HCPCS Level II October 2026 release.
Where is EC in the HCPCS Level II list?
EC is listed under Modifiers.
Does Medicare cover EC?
CMS lists EC’s Medicare coverage as “Special coverage instructions apply”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside EC
All modifiersE1Upper left, eyelidE2Lower left, eyelidE3Upper right, eyelidE4Lower right, eyelidEAErythropoietic stimulating agent (esa) administered to treat anemia due to anti-cancer chemotherapyEBErythropoietic stimulating agent (esa) administered to treat anemia due to anti-cancer radiotherapyEDHematocrit level has exceeded 39% (or hemoglobin level has exceeded 13.0 g/dl) for 3 or more consecutive billing cycles immediately prior to and including the current cycleEEHematocrit level has not exceeded 39% (or hemoglobin level has not exceeded 13.0 g/dl) for 3 or more consecutive billing cycles immediately prior to and including the current cycleEJSubsequent claims for a defined course of therapy, e.g., epo, sodium hyaluronate, infliximabEMEmergency reserve supply (for esrd benefit only)EPService provided as part of medicaid early periodic screening diagnosis and treatment (epsdt) programERItems and services furnished by a provider-based, off-campus emergency department